AU2009302344A1 - Treating Hepatitis C virus infection with over-expression of microRNA-196 - Google Patents

Treating Hepatitis C virus infection with over-expression of microRNA-196 Download PDF

Info

Publication number
AU2009302344A1
AU2009302344A1 AU2009302344A AU2009302344A AU2009302344A1 AU 2009302344 A1 AU2009302344 A1 AU 2009302344A1 AU 2009302344 A AU2009302344 A AU 2009302344A AU 2009302344 A AU2009302344 A AU 2009302344A AU 2009302344 A1 AU2009302344 A1 AU 2009302344A1
Authority
AU
Australia
Prior art keywords
mirna
hcv
expression
cells
mimic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009302344A
Other languages
English (en)
Other versions
AU2009302344A2 (en
Inventor
Herbert L. Bonkovsky
Weihong Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of AU2009302344A1 publication Critical patent/AU2009302344A1/en
Publication of AU2009302344A2 publication Critical patent/AU2009302344A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2009302344A 2008-10-08 2009-10-08 Treating Hepatitis C virus infection with over-expression of microRNA-196 Abandoned AU2009302344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10360908P 2008-10-08 2008-10-08
US61/103,609 2008-10-08
PCT/US2009/059944 WO2010042683A1 (en) 2008-10-08 2009-10-08 Treating hepatitis c virus infection with over-expression of microrna-196

Publications (2)

Publication Number Publication Date
AU2009302344A1 true AU2009302344A1 (en) 2010-04-15
AU2009302344A2 AU2009302344A2 (en) 2011-04-28

Family

ID=41559924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009302344A Abandoned AU2009302344A1 (en) 2008-10-08 2009-10-08 Treating Hepatitis C virus infection with over-expression of microRNA-196

Country Status (10)

Country Link
EP (1) EP2352829A1 (ja)
JP (1) JP2012505233A (ja)
KR (1) KR20110065568A (ja)
CN (1) CN102257140A (ja)
AR (1) AR073800A1 (ja)
AU (1) AU2009302344A1 (ja)
BR (1) BRPI0914060A2 (ja)
CA (1) CA2739948A1 (ja)
MX (1) MX2011003813A (ja)
WO (1) WO2010042683A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110724734B (zh) * 2019-10-22 2020-06-16 北京恩泽康泰生物科技有限公司 含miRNA mimic的人造脂质体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US8415323B2 (en) * 2007-08-27 2013-04-09 The Regents Of The University Of California MicroRNAs for inhibiting viral replication

Also Published As

Publication number Publication date
BRPI0914060A2 (pt) 2015-11-17
CA2739948A1 (en) 2010-04-15
CN102257140A (zh) 2011-11-23
AU2009302344A2 (en) 2011-04-28
EP2352829A1 (en) 2011-08-10
AR073800A1 (es) 2010-12-01
JP2012505233A (ja) 2012-03-01
MX2011003813A (es) 2011-07-28
KR20110065568A (ko) 2011-06-15
WO2010042683A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
US10041070B2 (en) MicroRNAs modulating the effect of glucocorticoid signaling
Wang et al. microRNA-20b contributes to high glucose-induced podocyte apoptosis by targeting SIRT7
EP3679138B1 (en) Hnf4a sarna compositions and methods of use
AU2009302344A1 (en) Treating Hepatitis C virus infection with over-expression of microRNA-196
Chen et al. Lnc-Ang362 is a pro-fibrotic long non-coding RNA promoting cardiac fibrosis after myocardial infarction by suppressing Smad7
Huang et al. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1
WO2016192669A1 (zh) 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用
US20110117181A1 (en) Treating hepatitis c virus infection with over-expression of microrna-196
WO2018210259A1 (zh) 一种调节食欲和体重的药物及它们的应用
WO2017084610A1 (zh) miR-183或其抑制剂的用途
CN113908280A (zh) Trim11抑制剂和二甲双胍的组合物在治疗肝细胞癌中的应用
US9850489B2 (en) Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity
WO2011074652A1 (ja) HIF-2αの発現を抑制する核酸
WO2014015824A1 (zh) 具有转录和转录后双水平基因沉默功能的microRNA的筛选方法
CN116769828B (zh) 调控nrf2转录因子活性的方法
KR101928427B1 (ko) 마이크로rna-497을 유효성분으로 포함하는 알코올성 간질환의 예방 또는 치료용 조성물 및 이의 스크리닝 방법
CN110652522B (zh) miR-2052在制备抗肝癌药物中的应用
US9163238B2 (en) Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
EP4244359A1 (en) B-spectrin (sptbn1) deficiency protects mice from high-fat diet-induced liver disease and cancer development
CN116392500A (zh) microRNA及其在诊断和治疗中的用途
Liu et al. MiR-203 is an Anti-Obese miRNA by Targeting ASBT
KR20090002560A (ko) ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAR 2011

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application